Can people with diabetes take fenelidone tablets?

Finerenone (Finerenone), as a new therapeutic drug, has shown excellent results in the treatment of diabetes and its related complications. It blocks the excessive activation of mineralocorticoids caused by aldosterone, inhibits inflammatory response, fibrosis, and delays damage to kidney structure and function. At the same time, fenelinone can also reduce the risk of adverse cardiovascular events and provide more treatment options for diabetic patients.

Finelidone received medicinal use authorization in the United States in July 2021 and in the European Union in February 2022. It is approved for the treatment of individuals with type 2 diabetes and chronic kidney disease (stages 3 and 4 of proteinuria). In brief studies including individuals with type 2 diabetes and chronic kidney disease, fenelidone was found to reduce proteinuria. Fenelidone may be a good treatment option for normotensive patients with diabetes and proteinuria. In a phase 2 study of fenelidone, a dose-dependent decrease in the urinary albumin to creatinine ratio was found. Fenelidone reduced the risk of cardiovascular and renal failure in patients with and without a history of cardiovascular disease, according to results from the Phase 3 randomized, placebo-controlled, double-blind FIDELIO-DKD study.

In summary, fenelidone, as a new type of therapeutic drug, has shown effectiveness in the treatment of diabetes and its related complications. It does not have a direct effect on lowering blood sugar, but it can be used as an effective drug in the treatment of type 2 diabetes and its complications. However, before using Fenelidone tablets, patients should consult their doctor and inform them if they are allergic to Fenelidone or have any allergic reactions to other medications.